Researchers make important discovery ”in the treatment of prostate cancer

It seems that Ozepic is not the only diabetes medicine that was raised with a secret sidehill.

A team of Swedish researchers has found that a drug traditionally intended for type 2 diabetes shows great promises in maintaining prostate cancer in the breast.

Research – which was published in the Molecular Cancer Journal – based on studies on mice, as well as a retrospective study of 69 patients with type 2 diabetes, all suffered a lack of recurrence of cancer while using the drug.

“This is a significant discovery,” said Lukas Kenner, a visiting professor at Umeã University of Sweden in a press release.

“For the first time, we have clinical observations that indicate that patients with prostate cancer with diabetes who took protein -target medicines [PPARy] It remained without relapse during the period that we followed. “

Pioglitazone-a common anti-diabetic drug-not just slowing the growth of cancer cells, but also impeded their ability to grow again.

“The findings are very promising, but further clinical studies are needed to confirm the results and investigate whether treatment can also be used in patients with no diabetes,” Kenner said.

It is the latest in a series of progress aimed at prostate cancer – the second most common cancer among men in the US, after skin cancer.

A UCLA study found that a tool identified prostate cancer with 84% accuracy, compared to 67% by doctors, emphasizing the potential of it in improving diagnostic accuracy.

A new home salivary test analyzes DNA for genetic markers associated with prostate cancer, providing a more accurate alternative to traditional blood tests and helps in previous detection.

And “after the shocking news that former President Joe Biden has a” fagressive “form of prostate cancer – a Manhattan doctor is offering free PSA blood tests at his Midtown East office by the end of June.

While the overall rate of five-year survival for prostate cancer is as high as 97%, studies have shown that men who avoid prostate cancer appointments are 45% more likely to die from the disease.